A case of pathological complete regression in combined modality treatment of resectable Her2/neu-positive gastric cancer

QR Code

A case of pathological complete regression in combined modality treatment of resectable Her2/neu-positive gastric cancer

Background. Overexpression of Her2neu occurs in 15–20% of patients with gastric cancer and correlates with an unfavorable prognosis. Case report. We report a case of pathological complete regression of resectable gastric cancer with Her2/neu overexpression. The patient received combined modality tre...

Full description

Saved in:

Bibliographic Details
Main Authors:	A. V. Avgustinovich, S. G. Afanasyev, L. V. Spirina, E. V. Kaygorodova, R. V. Ermolenko, E. N. Samtsov, I. G. Frolova, O. V. Cheremisina
Format:	Article
Language:	Russian
Published:	Russian Academy of Sciences, Tomsk National Research Medical Center 2024-03-01
Series:	Сибирский онкологический журнал
Subjects:	gastric cancer her2/neu overexpression combined modality treatment neoadjuvant therapy complete tumor regression
Online Access:	https://www.siboncoj.ru/jour/article/view/2970
Tags:	Add Tag No Tags, Be the first to tag this record!

Similar Items

NEW INDICATORS OF HSP27 FUNCTIONAL STATE IN BREAST CANCER CELLS WITH DIFFERENT VARIANTS OF HER2/NEU-STATUS
by: E. V. Kaigorodova, et al.
Published: (2016-02-01)

Possibilities of predicting the HER2 / neu status in a primary tumor in breast cancer patients using <sup>99m</sup>Tc-DARPinG3
by: O. D. Bragina, et al.
Published: (2023-01-01)

Assessing functional suitability of a lyophilized formulation containing designed ankyrin repeat proteins for radionuclide imaging of HER2/neu overexpression in malignant tumors
by: R. N. Varvashenya, et al.
Published: (2024-10-01)

The development of a highly specific radiochemical compound based on labeled 99mtc recombinant molecules for targeted imaging of cells with the overexpression of Her-2 / neu
by: Olga D. Bragina, et al.
Published: (2017-10-01)

EVALUATION OF EXTENT OF BREAST CANCER IN A PATIENT WITH HER2/NEU OVEREXPRESSION USING A RADIOPHARMACEUTICAL BASED ON TECHNETIUM-99M-LABELED TARGET MOLECULES (CASE REPORT)
by: O. D. Bragina, et al.
Published: (2021-10-01)

Clinical possibilities of HER2-positive breast cancer diagnosis using alternative scaffold proteins
by: O. D. Bragina, et al.
Published: (2022-10-01)

Immunomorphological specifcity of HER2-low breast cancer
by: I. V. Mikhailov, et al.
Published: (2024-11-01)

P435 HER2/neu-derived peptide conjugated to liposomes containing DOPE as an effective prophylactic vaccine formulation for breast cancer
by: Niloofar Farzad, et al.
Published: (2019-12-01)

A Mathematical Model for Complete Morphological Regression in Primary Operable HER2-Positive Breast Cancer
by: A. E. Orlov, et al.
Published: (2021-04-01)

Developing a predictive model for neoadjuvant therapy in HER2 overexpression breast cancer using multi-parameter MRI radiomics: two-center retrospective study
by: Lingling Wang, et al.
Published: (2025-07-01)

Possibilities of radionuclide diagnostics of Her2-positive breast cancer using technetium-99m-labeled target molecules: the first experience of clinical use
by: O. D. Bragina, et al.
Published: (2021-04-01)

Comparative Analysis of the Clinical Use of 99mTechnetium-Labeled Recombinant Target Molecules in Different Dosages for the Radionuclide Diagnosis of Her2-Positive Breast Cancer
by: O. D. Bragina, et al.
Published: (2021-06-01)

Pathologic Response and Survival Outcomes on HER2-Low vs. HER2-Zero in Breast Cancer Receiving Neoadjuvant Chemotherapy
by: Rumeysa Colak, et al.
Published: (2025-06-01)

A direct comparison of the diagnostic efficacy of alternative scaffoldbased radiopharmaceuticals [<sup>99m</sup>Tc]Tc-ADAPT6 and [<sup>99m</sup>Tc]Tc-(HE)<sub>3</sub>-G3 in patients with HER2-positive breast cancer
by: O. D. Bragina, et al.
Published: (2023-10-01)

EFFICACY OF COMBINED MODALITY TREATMENT INCLUDING NEOADJUVANT CHEMOTHERAPY IN PATIENTS WITH ESOPHAGEAL CANCER
by: Yu. V. Rudyk, et al.
Published: (2016-02-01)

Detection of serum HER2 in patients treated with neratinib or trastuzumab: analysis of the I-SPY Trial
by: Mark Hensley, et al.
Published: (2025-07-01)

Особливості експресії прогностичних маркерів р16й her2/new та зміни відповдних генів в окремих фенотипах раків невідомого первинного походження.
by: О. V. Poslavska, et al.
Published: (2019-09-01)

Improving treatment outcomes for patients with HER2‑positive breast cancer using neoadjuvant double HER2 blockade
by: V. F. Semiglazov, et al.
Published: (2024-11-01)

LONG-LASTING CONTROL OF HER-2 POSITIVE DISSEMINATED BREAST CANCER IN A REPRODUCTIVE AGED PATIENT
by: A. V. Vazhenin, et al.
Published: (2021-06-01)

De-escalated neoadjuvant nab-paclitaxel combined with pyrotinib and trastuzumab in intrinsic HER2-enriched breast cancer (NJMU-BC01): a multicenter, single-arm, phase 2 trialResearch in context
by: Hong Pan, et al.
Published: (2025-08-01)

CHEMOTHERAPY IN COMBINED MODALITY TREATMENT FOR LOCALLY ADVAMCED NON-SMALL CELL LUNG CANCER
by: Е. L. Yumov, et al.
Published: (2016-02-01)

دراسة بعض الماركرات في النساء العراقيات المريضات بسرطان الثدي
by: Abeer M. Hussain, et al.
Published: (2021-12-01)

Distribution-Free Normal Modal Logics
by: Chrysafis Hartonas
Published: (2025-04-01)

Immunohistochemical characteristics of breast cancer, increasing the risk of local reccurence after organosaving treatment
by: S. M. Demidov, et al.
Published: (2018-10-01)

Key studies that have changed the history and treatment of early HER2+ breast cancer: focus on individual therapy
by: I. V. Kolyadina, et al.
Published: (2021-01-01)

Immediate results of neoadjuvant chemotherapy for resectable colon cancer
by: D. I. Azovsky, et al.
Published: (2025-03-01)

Clinical significance of changes in the expression level of markers of surrogate breast cancer subtypes in recurrent and metastatic foci (literature review)
by: Yu. S. Krumin, et al.
Published: (2021-03-01)

Combined prognostic impact of initial clinical stage and residual cancer burden after neoadjuvant systemic therapy in triple-negative and HER2-positive breast cancer: an analysis of the I-SPY2 randomized clinical trial
by: Roberto A. Leon-Ferre, et al.
Published: (2025-06-01)

Spiking Neural Networks for Multimodal Neuroimaging: A Comprehensive Review of Current Trends and the NeuCube Brain-Inspired Architecture
by: Omar Garcia-Palencia, et al.
Published: (2025-06-01)

INTRATUMORAL AMPLIFICATION HETEROGENEITY IN HER2/neu-POSITIVE BREAST CANCER MOLECULAR-GENETIC SUBTYPES
by: L. N. Vashchenko, et al.
Published: (2019-11-01)

Short-term efficacy and toxicity of total neoadjuvant chemotherapy in patients with resectable gastric cancer
by: A. V. Avgustinovich, et al.
Published: (2022-03-01)

Application of multicolor flow cytometry in liquid biopsy of breast cancer
by: E. V. Kaigorodova, et al.
Published: (2023-10-01)

Achievement of complete morphological regression in the use of trastuzumab in patients with inoperable locally advanced Her-2+ breast cancer
by: K. R. Zeinalova, et al.
Published: (2014-07-01)

NEU1-Mediated Extracellular Vesicle Glycosylation in Alzheimer’s Disease: Mechanistic Insights into Intercellular Communication and Therapeutic Targeting
by: Mohd Adnan, et al.
Published: (2025-06-01)

Clinicopathological Characteristics of HER2-Positive Breast Cancer Patients with BRCA1/2 Pathogenic Variants and Their Response to Neoadjuvant Targeted Therapy
by: Xingyu LIAO, et al.
Published: (2025-06-01)

Review of Structural Modal Tracking in Operational Modal Analysis: Methods and Applications
by: Shenghui Fu, et al.
Published: (2025-06-01)

Morphological and molecular biological features of the mammary gland: a modern view
by: G. A. Demyashkin, et al.
Published: (2025-03-01)

Impact of pathological complete response following neoadjuvant chemotherapy (gemcitabine, nab-paclitaxel, S-1) and radiation for borderline resectable pancreatic cancer: a case report and review of literature
by: Mitsuru Kinoshita, et al.
Published: (2022-09-01)

German New Guinea : the annual reports /
Published: (1979)

HER2-positive breast cancer with invasive micropapillary carcinoma component shows immunosuppressive microenvironment and resistance to neoadjuvant therapy
by: Lulu Zhang, et al.
Published: (2025-08-01)